Clinical Trials Browser

Completed × Carcinoma, Non-Small-Cell Lung × capmatinib × Clear all

Bronchial Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04677595 2026-03-31

GeoMETry-C

Phase 2 Completed

36 enrolled 26 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04575025 2025-09-15

Special Drug Use-results Surveillance of Tabrecta Tablets

Completed

109 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02414139 2024-03-20

Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

Phase 2 Completed

373 enrolled 34 charts 2 FDA

Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT05675683 2023-01-09

Real-World Assessment of Clinical Outcomes in Metastatic NSCLC Patients With MET Exon 14 Skipping Mutation and Brain Metastases Treated With Capmatinib

Completed

68 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05154344 2023-01-06

CapmATU

Completed

182 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03647488 2022-01-24

Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer

Phase 2 Completed

18 enrolled 23 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01911507 2021-10-13

INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer

Phase 1 Completed

35 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01610336 2021-04-08

A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment

Phase 2 Completed

161 enrolled 32 charts

Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01324479 2020-12-19

Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors

Phase 1 Completed

131 enrolled

CNSThoracic

Carcinoma, Non-Small-Cell Lung, Glioblastoma

Clinical Trials

Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.

GeoMETry-C

Special Drug Use-results Surveillance of Tabrecta Tablets

Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

Real-World Assessment of Clinical Outcomes in Metastatic NSCLC Patients With MET Exon 14 Skipping Mutation and Brain Metastases Treated With Capmatinib

CapmATU

Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer

INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer

A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment

Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors